Interscope Medical, a medical device firm focused on devices used for ENT and gastrointestinal treatment, announced today the FDA approval for their EndoRotor System to commercialize pulmonary indications.
Interscope were the first innovators of the flexible microdebrider for use by medical specialists in the digestive tract that let to results reducing the need for surgery.
Jeffery Ryan, CEO of Interscope made a statement on the following,
“We are extremely excited to be able to offer this therapy, building on the efficacy of other microdebrider OEMs whose devices were limited to the central airway. EndoRotor provides customers with a means to access distal lesions using the proven concept of micro debridement. We are excited to continue to build on the success of introducing the first ever flexible shaver for pulmonary procedures. We are continuing to propel advancements in interventional endoscopic and minimally invasive care.”
According to iData Research, the ENT endoscopic and bronchoscopic deivce market has experienced steady growth in recent years. Recently, there has been a trend in the U.S where procedures are being more commonly performed in office settings. The increase in office procedures has led to an increase in the number of units sold, as physicians need to purchase the equipment required to perform the procedures. This trend towards office procedures is driving the overall ENT endoscopic and bronchoscopic device market.
The EndoRotor System is active in the management of gastrointestinal mucosal disease at leading medical centers in Germany, United Kingdom, Netherlands, Switzerland, and Austria.
For Further Information
To get in an in-depth market overview and to see an extensive portfolio of innovations in technology, please read iData Research’s’ 297 page U.S. ENT Devices Market Analysis, Size and Trends Report.